GSK’s announces new data for Arexvy at RSVVW’26

GSK (GSK) announced new effectiveness data for its adjuvanted recombinant respiratory syncytial virus vaccine at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK’s leadership in research and prevention of RSV. For GSK’s RSV vaccine, the study showed an association with 75.6% vaccine effectiveness against RSV-related hospitalisation at a median follow-up of 5.6 months post-vaccination. Further exploratory endpoints showed an association with 63.1% VE against major adverse cardiovascular events, including heart attack and stroke, during RSV-related hospitalisation among adults aged greater than or equal to 60 years